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8.1. General
Proctocolectomy with ileal pouch-anal anastomosis (IPAA)
is the procedure of choice for most patients with ulcerative
colitis (UC) requiring colectomy.1 Pouchitis is a non-specific
inflammation of the ileal reservoir and the most common
complication of IPAA in patients with UC.2–7 Its frequency is
related to the duration of the follow-up, occurring in up to
50% of patients 10 years after IPAA in large series from
major referral centres.1–9 The cumulative incidence of
pouchitis in patients with an IPAA for familial adenomatous
polyposis is much lower, ranging from 0 to 10%.10–12
Reasons for the higher frequency of pouchitis in UC remain
unknown. Whether the pouchitis more commonly develops
within the first years after IPAA or whether the risk
continues to increase with longer follow-up remains
undefined.ECCO Statement 8A
The diagnosis of pouchitis requires the presence of
symptoms, together with characteristic endoscopic and
histological abnormalities [EL3a, RGB]. Extensive colitis,
extraintestinal manifestations (eg primary sclerosing cho-
langitis), being a non-smoker, p-ANCA positive serology, and
non-steroidal anti-inflammatory drug use are possible risk
factors for pouchitis [EL3b, RG D ]8.1.1. Symptoms
After total proctocolectomy with IPAA, median stool
frequency is 4 to 8 bowel movements1–4,13,14 with 700 mLof semiformed/liquid stool per day2,13,14. Symptoms related
to pouchitis include increased stool frequency and liquidity,
abdominal cramping, urgency, tenesmus and pelvic dis-
comfort (2, 15). Rectal bleeding, fever, or extraintestinal
manifestations may occur. Rectal bleeding is more often
related to inflammation of the rectal cuff (“cuffitis”),16
than to pouchitis. Poor faecal incontinence may occur in the
absence of pouchitis after IPAA, but is more common in
patients with pouchitis. Symptoms of pouch dysfunction in
patients with IPAA may be caused by conditions other than
pouchitis, including Crohn's disease of the pouch,17–19
cuffitis,16 and an irritable pouch.20 This is why the diagnosis
depends on endoscopy and biopsy in conjunction with
symptoms.
8.1.2. Endoscopy (‘pouchoscopy’)
Pouchoscopy and pouch mucosal biopsy should be per-
formed in patients with symptoms compatible with
pouchitis, in order to confirm the diagnosis.15 Patients
with an ileoanal pouch occasionally have a stricture at the
pouch-anal anastomosis, so a gastroscope rather than a
colonoscope may better be necessary for pouchoscopy.
Endoscopic findings compatible with pouchitis include
diffuse erythema caused by inflammation of the ileal
pouch, which may be patchy, unlike that observed in UC.
Characteristic endoscopic findings include oedema, gran-
ularity, friability, spontaneous or contact bleeding, loss of
vascular pattern, mucous exudates, haemorrhage, erosions
and ulceration.17 Erosions and/or ulcers along the staple
line do not necessarily indicate pouchitis. Characteristi-
cally, these findings are non-specific and lesions may be
discontinuous, unlike the colorectal lesions in UC.18,21,22
Biopsies should be taken from the pouch mucosa and from
the afferent limb above the pouch, but not along the
staple line.
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Histological findings of pouchitis are also non-specific,
including acute inflammation with polymorphonuclear
leukocyte infiltration, crypt abscesses and ulceration, in
association with a chronic inflammatory infiltrate.21,22
There may be discrepancy between endoscopic and
histologic findings in pouchitis, possibly related to sam-
pling error.23,24 Morphological changes of the epithelium
lining the ileal pouch normally develop in the 12–18 months
after ileostomy closure, characterised by flattening and a
reduced number, or disappearance of the villi, leading to
villous atrophy (“colonic metaplasia”).22–24 Although the
aetiology of pouchitis remains unknown, it can be inferred
from the predeliction for patients with UC and the
response to antibiotic therapy that the bacterial flora
and whatever predisposes to UC itself are involved in the
pathogenesis of tissue damage in the ileoanal pouch.25,26
Pouchitis tends to occur only after colonic metaplasia has
developed in the pouch, although a causal association is
unproven.ECCO Statement 8B
The most frequent symptoms of pouchitis are increased
number of liquid stools, urgency, abdominal cramping
and pelvic discomfort. Fever and bleeding are rare [EL1c,
RG B]. Routine pouchoscopy after clinical remission is not
required [EL5, RG D]8.1.4. Differential diagnosis
The clinical history and biopsies help discriminate between
pouchitis, ischaemia, Crohn's disease (CD) and other rare
forms of pouch dysfunction such as collagenous pouchitis,
Clostridium difficile or cytomegalovirus pouchitis.27–29
Secondary pouchitis, caused by pelvic sepsis, usually causes
focal inflammation and should be considered. Biopsies taken
from the ileum above the pouch may reveal pre-pouch ileitis
as a cause of pouch dysfunction, although this usually causes
visible ulceration that may be confused with Crohn's
disease.30 The possibility of non-specific ileitis caused by
NSAIDs should be considered.31
8.1.5. Risk factors for pouchitis and pouch dysfunction
Reported risk factors for pouchitis include extensive UC,1,32
backwash ileitis,32 extraintestinal manifestations (especially
primary sclerosing cholangitis),5,19,33 being a non-smoker34
and regular use of NSAIDs.31,35 Interleukin-1 receptor antago-
nist gene polymorphisms36 and the presence of perinuclear
neutrophil cytoplasmic antibodies37 are also associated with
pouchitis. Not surprisingly studies are discordant with regard
to the role of each risk factor. Some of the best data on risk
factors come from the Cleveland Clinic.38 240 consecutive
patients were classified as having healthy pouches (n=49),
pouchitis (n=61), Crohn's disease (n=39), cuffitis (n=41), or
irritable pouch syndrome (n=50). The risk of developing
pouchitis was increased 3–5 fold when the indication for IPAA
was dysplasia (OR 3.89; 95% CI 1.69–8.98), or when the patient
had never smoked (OR 5.09; 95% CI 1.01–25.69), or used
NSAIDs (OR 3.24; 95% CI 1.71–6.13), or (perhaps surprisingly)
had never used anxiolytics (OR 5.19; 95% CI 1.45–18.59). The
risk of turning out to have Crohn's disease of the pouch was
greatly increased by being a current smoker (OR 4.77; 95% CI,1.39–16–25), and modestly associated by having a pouch of
long duration (OR 1.20; 95% CI 1.12.–1.30). Cuffitis was
associated with symptoms of arthralgia (OR 4.13; 95% CI 1.91–
8.94) and a younger age (OR 1.16; 95% CI 1.01–1.33). Irritable
pouch syndrome is probably under-recognised, although is a
common cause of pouch dysfunction when other causes
(including a small volume pouch, incomplete evacuation and
pouch volvulus) have been excluded and investigations are
normal. The principal risk factor is the use of antidepressants
(OR 4.17; 95% CI 1.95–8.92) or anxiolytics (OR 3.21; 95% CI
1.34–7.47), which suggests that these people may have had
irritable bowel syndrome contributing to symptoms of colitis
before pouch surgery.38
These risk factors should not preclude proctocolectomy if
surgery is appropriate, but should inform pre-operative
discussions with the patient and family. In particular the
possibility that IBS may be contributing to symptoms of
refractory UC should be considered and objective evidence
of treatment refractory colitis obtained before surgery. If
there is a disparity between preoperative and endoscopic
appearance, or if the patient is on antidepressants, then the
risk of pouch dysfunction after IPAA needs particularly
careful consideration. Similarly, if a patient has primary
sclerosing cholangitis, then it is appropriate to discuss the
higher risk of pouchitis. This is appropriate management of
expectations rather than a contraindication to appropriate
surgery.
8.2. Pattern of pouchitis
8.2.1. Acute and chronic pouchitis
On the basis of symptoms and endoscopy, pouchitis can be
divided into remission (normal pouch frequency) or active
pouchitis (increased frequency with endoscopic appear-
ances and histology consistent with pouchitis).15,39 Active
pouchitis may then be divided into acute or chronic,
depending on the symptom duration. The threshold for
chronicity is a symptom duration of N4 weeks. Up to 10% of
patients develop chronic pouchitis requiring long-term
treatment, and a small subgroup has pouchitis refractory
to medical treatment.3
8.2.2. Scoring of pouchitis
The Pouchitis Disease Activity Index (PDAI) has been
developed to standardize diagnostic criteria and assess the
severity of pouchitis.15,39,40 The PDAI is a composite score
that evaluates symptoms, endoscopy and histology. Each
component score has a maximum of 6 points. Patients with a
total PDAI score ≥7 are classified as having pouchitis, so a
patient has to have both symptoms and endoscopic or
histological evidence of pouchitis and, ideally, all three.
The problem is that about a quarter of patients with a high
symptom score suggestive of pouchitis may not fulfil criteria
for the diagnosis of pouchitis, as assessed by the PDAI, since
endoscopic or histological criteria may be absent. Conse-
quently a relatively large number of patients may be
unnecessarily treated for puchitis when symptoms are due
to other conditions. Other scoring systems have been
devised, including that by Moskowitz21 and an index from
Heidelberg. Comparisons with the PDAI41,42 show that they
are not interchangeable, but this affects clinical trials rather
than clinical practice.
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Pouchitis recurs in more than 50%.3,15,39 Patients with
recurrent pouchitis can broadly be grouped into three
categories: infrequent episodes (b1/yr), a relapsing course
(1–3 episodes/yr) or a continuous course. Pouchitis may
further be termed treatment responsive or refractory, based
on response to single-antibiotic therapy (see 8.3.2).7,9
Although these distinctions are largely arbitrary, they help
both patients and their physicians when considering manage-
ment options to alter the pattern of pouchitis. Complications
of pouchitis include abscesses, fistulae, stenosis of the
pouch-anal anastomosis and adenocarcinoma of the
pouch.7,27,39 This latter complication is exceptional and
almost only occurs when there is pre-exiting dysplasia or
carcinoma in the original colectomy specimen.
8.3. Medical treatment
8.3.1. Acute pouchitis: antibioticsECCO Statement 8C
The majority of patients respond to metronidazole or
ciprofloxacin, although the optimum modality of treat-
ment is not clearly defined [EL1b, RG B]. Side-effects are
less frequent using ciprofloxacin [EL1c, RG B]. Antidiar-
rhoeal drugs may reduce the number of daily liquid stools
in patients, independent of pouchitis [EL5, RGD]Treatment of pouchitis is largely empirical and only small
placebo-controlled trials have been conducted. Antibiotics are
the mainstay of treatment, and metronidazole and ciproflox-
acin are the most common initial approaches, often with a
rapid response. The odds ratio of inducing a response using oral
metronidazole compared with placebo in active chronic
pouchitis was 26.67 (95% CI 2.31–308.01, NNT=2).43 The
randomised trials of bothmetronidazole and ciprofloxacin are,
however, small.44–46 The two have been compared in another
small randomised trial.47 Seven patients received ciproflox-
acin 1 g/day and nine patients metronidazole 20 mg/kg/day
for a period of 2 weeks. Ciprofloxacin lowered the PDAI score
from10.1±2.3 to 3.3±1.7 (p=0.0001),whereasmetronidazole
reduced the PDAI score from 9.7±2.3 to 5.8±1.7 (p=0.0002).
Therewas a significantly greater reduction in the ciprofloxacin
compared to metronidazole in terms of the total PDAI
(p=0.002), symptom score (p=0.03) and endoscopic score
(p=0.03), as well as fewer adverse events (33% of metronida-
zole-treated patients reported side-effects, but none on
ciprofloxacin). Combination antibiotic therapy is an option
for persistent symptoms (below).
8.3.2. Chronic pouchitis: combination antibiotic therapy
or budesonideECCO Statement 8D
In chronic pouchitis, combined antibiotic treatment is
effective [EL1b, RG B]For patients who have persistent symptoms, alternative
diagnoses should be considered, including undiagnosed
Crohn's disease, pouch-anal or ileal-pouch stricture, infec-tion with CMV or Cl difficile, collagenous pouchitis, cuffitis,
anatomical disorders, or irritable pouch syndrome. Approxi-
mately 10–15% of patients with acute pouchitis develop
chronic pouchitis, which may be “treatment responsive” or
“treatment refractory” to single-antibiotic therapy.39
Patients with chronic, refractory pouchitis do not respond
to conventional therapy and often continue to suffer
symptoms, which is a common cause of pouch failure.
Combination antibiotic therapy or oral budesonide may
work. 16 consecutive patients with chronic, refractory
pouchitis (disease N4 weeks and failure to respond to
N4 weeks of single-antibiotic therapy) were treated with
ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day for
4 weeks.47 A historic cohort of ten consecutive patients with
chronic refractory pouchitis treatedwith 5–8 g oral and topical
mesalazine daily was used as a comparator. These refractory
patients had a significant reduction in the total PDAI score and
a significant improvement in quality-of-life score (pb0.002)
when taking ciprofloxacin and tinidazole, compared to base-
line. The rate of clinical remission in the antibiotic group was
87.5% and for the mesalazine group was 50%.
In another study, 18 patients non-responders to metroni-
dazole, ciprofloxacin or amoxycillin/clavulanic acid for
4 weeks were treated orally with rifaximin 2 g/day (a
nonabsorbable, broad spectrum antibiotic) and ciprofloxacin
1 g/day for 15 days. Sixteen out of 18 patients (88.8%) either
improved (n=10) or went into remission (n=6).48 Median
PDAI scores before and after therapy were 11 (range 9–17)
and 4 (range 0–16), respectively (pb0.002). A British group
observed similar benefit in just 8 patients.49 In another
combination study, 44 patients with refractory pouchitis
received metronidazole 800 mg–1 g/day and ciprofloxacin
1 g/day for 28 days.50 36 patients (82%) went into remission
andmedian PDAI scores before and after therapy were 12 and
3 respectively (pb0.0001). The alternative is oral budeso-
nide CIR 9 mg daily for 8 weeks, which achieved remission in
15/20 (75%) patients not responding after 1 month of
ciprofloxacin or metronidazole.51 The message is simple
enough, even if the trials are underpowered: if ciprofloxacin
does not work, then try it in combination with an imidazole
antibiotic or rifaximin, or try oral budesonide.
8.3.3. Acute and chronic refractory pouchitis: other
agents
The variety of approaches illustrates the challenges of trying
to find treatment that works for a new disorder. These are
largely of historic interest. Budesonide enemas were as
effective as metronidazole for acute pouchitis in a rando-
mised controlled trial.52 Ciclosporin enemas were successful
for chronic pouchitis in a pilot study53 and oral azathioprine
may help if patients relapse become budesonide-dependent.
Uncontrolled studies of short-chain fatty acid enemas54,55
showed little value. Glutamine and butyrate suppositories
have been compared for chronic pouchitis.56 Of more recent
interest, infliximab has been tried in patients with chronic,
(very) refractory pouchitis not responding either to metro-
nidazole or ciprofloxacin 1 g/day for 4 weeks or oral
budesonide CIR 9 mg/day for 8 weeks. 10/12 (83.3%) such
patients treated with infliximab 5 mg/kg at 0, 2 and 6 weeks
went into remission.57 The median PDAI score before therapy
was 13 (range 8–18) and 2 (range 0–9) after infliximab
(pb0.001) and the IBDQ also significantly improved from 96
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been used when the cause of pouch dysfunction is Crohn's
disease, or fistulation. 58 Benefit been also been reported
from alicaforsen enemas (an inhibitor of intercellular
adhesion molecule (ICAM)-1) in an open-label trial.59
8.3.4. Maintenance of remission: probioticsECCO Statement 8E
VSL#3 (18 × 10 11 of 8 bacterial strains for 9 or 12 months)
has shown efficacy for maintaining antibiotic-induced
remission [EL1b, RG B]. VSL#3 (9 ×1011 bacteria) has also
ECCO Statement 8E
Rectal cuff inflammation (cuffitis) may induce symptoms
similar to pouchitis or irritable pouch syndrome, although
bleeding is more frequent [EL2a, RG B]. Topical 5-ASA has
ECCO Statement 9A
Patients with longstanding ulcerative colitis appear to have
an increased risk of colorectal cancer (CRC) as compared toIn chronic pouchitis, once remission has been obtained,
treatment with the highly concentrated probiotic mixture
VSL#3 is able to maintain remission. Two double-blind,
placebo-controlled studies have shown the efficacy of
VSL#3 (450 billion bacteria of 8 different strains/g) to
maintain remission in patients with chronic pouchitis. In the
first study, 40 patients who achieved clinical and endo-
scopic remission after one month of combined antibiotic
treatment (rifaximin 2 g/day+ciprofloxacin 1 g/day), were
randomised to receive either VSL#3, 6 g/day (18×1011
bac teri a/ day), or placebo for 9 mo nths.60 All 20 patient s
who received placebo relapsed, while 17 of the 20 patients
(85%) treated with VSL#3 remained in clinical and endo-
scopic remission at the end of the study. Interestingly, all 17
patients relapsed within four months after stopping
VSL#3.60 In the second study, 36 patients with chronic,
refractory pouchitis who achieved remission (PDAI =0)
after 1 month of combined antibiotic treatment (metroni-
dazole+ciprofloxacin) received 6 g/once a day of VSL#3 or
placebo for 1 year. Remission rates at one year were 85% in
the VSL#3 group and 6% in the placebo group (pb0.001).61
8.3.5. Prevention of pouchitis: probiotics
The same probiotic preparation (VSL#3) has been shown to
prevent pouchitis within the first year after surgery, in a
randomised, double-blind, placebo-controlled study. Forty
consecutive patients undergoing IPAA for UC were rando-
mised within a week after ileostomy closure, to VSL#3 3 g
(9 × 10 11 ) per day or placebo for 12 months. Patients were
assessed clinically, endoscopically and histologically at 1, 3,
6, 9 and 12 months. Patients treated with VSL#3 had a
si gni fi can tly l ower i nc ide n ce o f a cu te pou chi ti s ( 10 %)
compared with those treated with placebo (40%) ( p b 0.05),
and experienced a significant improvement of quality of
life.62 The mechanism by which therapy with probiotics
works remains elusive, but has been investigated.63 Mucosa-
associated pouch microbiota before and after therapy with
VSL#3 shows that patients who develop pouchitis while
treated with placebo have low bacterial and high fungal
diversity. Bacterial diversity was increased and fungal
diversity was reduced in patients in remission maintained
with VSL#3 (p=0.001). Real time PCR experiments demon-
strated that VSL#3 increased the total number of bacterial
cells (p=0.002) and modified the spectrum of bacteria
towards anaerobic species. Taxa-specific clone libraries
showed that the spectrum of Lactobacillus sp. and Bifido-
bacter sp. was altered on probiotic therapy. The diversity of
the fungal flora was repressed. Restoration of the integrity of
shown efficacy for preventing pouchitis [EL2b, RG C]a “protective” intestinal mucosa related microbiota could
therefore be a potential mechanism of probiotic bacteria in
inflammatory barrier diseases of the lower gastrointestinal
tract.
8.4. CuffitisCuffitis, especially after double-stapled IPAA (see Section
7, preceding paper same issue) can cause pouch dysfunction
with symptoms that mimic pouchitis or irritable pouch
syndrome (IPS). Unlike IPS (which may coexist) bleeding is
a characteristic feature of cuffitis. Endoscopy by an informed
endoscopist is diagnostic, but care has to be taken to
examine the cuff of columnar epithelium between the
dentate line and pouch-anal anastomosis (Section 7.2.3,
preceding paper same issue).64 In an open-label trial, 14
consecutive patients with cuffitis were treated with mesa-
lamine suppositories 500 mg twice daily.16 Mesalazine
suppositories significantly reduced the total Cuffitis Activity
Index (derived from the PDAI) from 11.9±3.17 to 6.21±3.19
(pb0.001). Symptom subscore (from 3.24±1.28 to 1.79±
1.31), endoscopy subscore (from 3.14±1.29 to 1.00±1.52)
and histology subscore (4.93±1.77 to 3.57±1.39) were all
significantly reduced. 92% of patients with bloody bowel
movements and 70% with arthralgia (a characteristic clinical
feature of cuffitis, Section 8.1.5) improved on therapy. No
systemic or topical adverse effects were reported.
9. Surveillance for colorectal cancer
9.1. Risk of cancer
9.1.1. Estimation of risk
shown efficacy [EL4, RGD]Patients with long standing UC have a higher risk of
developing colorectal carcinoma (CRC) than the average
population. The magnitude of this risk, however, is still the
subject of a debate. Indeed, while older reports included in
two meta-analyses65,66 confirmed a rapid increase of the risk
after ten years of disease, the magnitude of the risk in recent
population-based studies appears much smaller.67,68 In fact,
although Eaden and colleagues computed a cumulative CRC
risk of 18% in UC patients after 30 years of disease, risks of
only 7.5% and 2.1% respectively were observed in two studies
published since 2004.67,68 Furthermore, in the largest report
of surveillance colonoscopy in at-risk population of patients
with extensive UC to date (600 patients over a 30 year
period), the cumulative incidence of CRC by colitis duration
the general population [EL2]
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40 years.69 In this study from St Mark's, only 30/600 patients
(5%) developed CRC. The reasons for such an improvement in
the risk of CRC are still unclear but may include improved
control of mucosal inflammation, more extensive use of 5-
ASA compounds, the implementation of surveillance pro-
grammes and timely colectomy.70 Taken together these
studies suggest that the CRC risk in UC patients should be
kept under scrutiny. Nevertheless, the best evidence, as
provided by concordant meta-analyses, indicates that the
risk of CRC development is increased in UC [EL2]. The ECCO
Consensus working party, through their answers to ques-
tionnaires, supported this evaluation of the data.
9.1.2. Risk factors for cancer developmentECCO Statement 9B
Risk is highest in patients with extensive colitis,
intermediate in patients with left-sided colitis, and not
increased in proctitis [EL2].
ECCO Statement 9D
Surveillance colonoscopy may permit earlier detection of
CRC, with a corresponding improved prognosis [EL3, RG
B]. Unequivocal evidence that surveillance colonoscopy
prolongs survival in patients with UC is lacking [EL3, RG B]Several independent factors affect the magnitude of the
risk of malignant transformation. The duration of disease and
extent of mucosal inflammation are the most prominent.
There is no uniform definition of the duration of disease,
although onset of symptoms has generally been used in the
studies that have identified this parameter as a risk factor. In
a review of 19 practice and population-based studies, Eaden
confirmed that the CRC risk appears to increase 8–10 years
after the onset of UC related symptoms65 and subsequently
increases in later decades of the disease [EL2].ECCO Statement 9C
Patientswith early onset of disease (ageb20 years at onset of
disease) and patients with UC-associated primary sclerosing
cholangitis (PSC)mayhaveaparticularly increased risk [EL2].
Persistent inflammation and family history of CRC may
contribute to the risk of CRC in patients with UC [EL3]The extent of mucosal inflammation (including backwash
ileitis) has been correlated with the risk of CRC in several
studies, as well as in a systematic review [EL2].66,67,71–75
Other factors have also been associatedwith a high CRC risk in
all or part of these studies. These include young age at onset
of the disease (less than 20 years of age at the time of
diagnosis)65 and an association with primary sclerosing
cholangitis (PSC) [EL2].76 However, there was no difference
in median age at onset of colitis for those with or without CRC
in the 600-patient study from St Mark's (p=0.8, Mann–
Whitney) years.69 The persistence of mucosal inflamma-
tion72,73 or a family history of CRC77 may also contribute to an
increased risk, but the association has been less consistent
across the studies [EL3]. In a nested case-control study from
twowell-defined, population-based IBD cohorts (Copenhagen
County, Denmark and Olmsted County, Minnesota) 43 cases of
IBD-associated CRC were matched on six criteria to 1–3
controls (n=102). Significant associations were found
between PSC (OR 6.9, 95% CI 1.2–40.0), the percentage of
time with clinically active disease (OR per 5% increase 1.2,95% CI 1.0–1.4), and≥12months of continuous symptoms (OR
3.2 95% CI 1.2–8.6).78 The presence of pseudopolyps, which
can be considered amarker of severity of inflammation, have
been associated with double the risk of CRC (OR 2.5; 95% CI:
1.4–4.6),73,79 which is a useful practice point for clinicians.
9.2. Surveillance colonoscopy programmes
9.2.1. Screening and surveillance
Since dysplastic changes in colonic mucosa are associated
with an increased risk of CRC in UC, surveillance colonoscopy
programmes have been developed with the aim of reducing
morbidity and mortality due to CRC, while avoiding
unnecessary prophylactic colectomy. Surveillance for CRC
in patients with UC amounts to more than just performing
repeated colonoscopies, but includes reviewing patient
symptoms, medication use and laboratory values as well as
updating personal and familial medical history. At the onset
of these programmes, an initial screening colonoscopy is
performed, with the goal of reassessing disease extent and
confirming the absence of dysplastic lesions. Thereafter
surveillance colonoscopies are regularly performed at
defined intervals (below).
9.2.2. EffectivenessThe effectiveness of these programmes has been eval-
uated in some prospective studies, systematically reviewed
by the Cochrane collaboration.66 An American consensus
conference, held under the auspices of the Crohn's and
Colitis Foundation of America, also reviewed the usefulness
of screening and surveillance colonoscopies in 2005.80 The
Cochrane collaboration used death related to CRC as the
primary endpoint for the evaluation of surveillance pro-
grammes in UC, limiting their analysis to prospective
randomised studies that included a control group. The
authors were unable to demonstrate a benefit of surveillance
programmes for preventing CRC-related death in UC by these
strict parameters, but included only two studies in their final
analysis.81,82 An earlier meta-analysis included a third study
yet to be published in full, but concluded that there was an
improved 5-year survival in patients undergoing surveillance,
compared to UC patients outside surveillance programmes.83
Furthermore, in the largest and most meticulous screening
programme reported to date, involving 600 patients, 2627
colonoscopies, 5932 patient-years of follow-up and a caecal
intubation rate of 98.7%, with no significant complications,
16/30 cancers were interval cancers.69
Unequivocal evidence for the benefit of these programmes
is therefore lacking and the apparent benefit could still be
linked to lead-time bias. Patients in surveillance programmes
may have an earlier diagnosis of CRC even if CRC is detected
independently of surveillance colonoscopy. Diagnosis of CRC in
patients outside such programmes may arise from later,
ECCO Statement 9G
If primary sclerosing cholangitis (PSC) is associated to
UC, surveillance should be performed annually from the
time of PSC diagnosis [EL3, RG B]
70 L. Biancone et al.symptom-driven investigation [EL3]. These issues are best
discussed with patients before entry into a surveillance
programme.
The Consensus had divided opinions regarding the ability
of surveillance colonoscopy programmes to improve survival
in UC patients, in keeping with the contrasting results of the
meta-analyses. Only one third of the voting experts
considered that the procedure could achieve this goal,
while two-thirds remained unconvinced or attributed any
benefit to potential lead-time bias. Nevertheless, it should
be noted that any benefit estimated in years of life saved
may be much greater in UC patients than for general
population screening. This is because UC-related CRC tends
to occur earlier in life and with a higher frequency than in the
general population. Mathematical models have evaluated
that the duration of life saved per case screened ranges from
1.2 to 5 years in UC patients, compared to 1.2 to 4 months in
general population screening,66,84 depending on the para-
meters included in the calculation.
9.2.3. Initial screening colonoscopyECCO Statement 9E
Screening colonoscopy should be offered 8–10 years after
the onset of UC symptoms to all patients to reassess diseaseAs duration of disease is a major risk factor for the
development of CRC in UC patients, it is rational to propose a
screening colonoscopy when the risk starts to increase, i.e.
after 8–10 years from the onset of disease [EL2]. This initial
colonoscopy also aims to reassess the extent of disease, since
this parameter also impacts on the risk of CRC. Nevertheless,
the appropriateness of screening colonoscopy as a way of
reassessing disease extent and potential risk has not been
formally established. It has been proposed in reviews and a
prior consensus report,80 as well as being agreed during the
present Consensus conference by the participating experts
[EL5].
9.2.4. Surveillance schedules
extent [EL5, RG D]ECCO Statement 9F
In extensive colitis, surveillance should start after
screening colonoscopy and be performed every other year
up to year 20 of disease, then annually [EL2, RG B].
Surveillance should start 15 years after onset of disease in
left-sided or distal UC. Proctitis does not require further
surveillance [EL2, RG B]The surveillance schedule is also arbitrary, but because CRC
has been observed within 2 years of surveillance colono-
scopy,85,86 intervals between repeat investigations should not
exceed this and should be shorter in patients with particularly
high risks such as those with longstanding disease or PSC.
Furthermore, although disease extent is central to CRC
risk assessment, this parameter may be difficult to define,
implying that surveillance may be offered to large groups of
patients. Considerable differences between extent assessed
by colonoscopy and histology have been reported,87 as wellas variations in extent over time.88 Neoplasia has been
reported in areas of microscopic involvement without
endoscopically visible inflammation. Thus, disease extent
should be defined not only by the outcome of screening
colonoscopy, but also by the results of previous procedures.
In contrast, there is good evidence that the CRC risk is lower
in patients with limited disease71,75 as defined by colono-
scopy or barium enema, so a reasonable compromise is to
defer surveillance until later time points in patients with
limited macroscopic disease [EL2]. This all assumes that a
decision has been made with the patient that surveillance is
appropriate. If the risk of CRC complicating colitis is thought
to be no higher than the general population, surveillance
may be considered unnecessary.In other situations, such as patients with UC-associated
PSC, the risk of developing a CRC is not only particularly high,
but has been reported to occur early (median 2.9 years) in
the course of the disease.89 These patients should enter in a
more intensive surveillance programme once the diagnosis of
PSC has been established.
The recommendations by ECCO (Statements 9E–9G) are
contingent on a perceived increased risk of CRC in UC
(Statements 9A–9C) and widespread acceptance in several
European countries that screening for CRC in the general
population is appropriate. If the latter applies, it is difficult
to justify failure to screen a group of patients with higher risk
of CRC more closely. The recommendation grades are
appropriate to the strength of the evidence.
9.3. Colonoscopic procedures
9.3.1. Number and site of biopsies
Evidence for procedural techniques during surveillance
colonoscopy is better documented than the benefit of the
programme itself. At least 33 biopsies should be obtained
from the various segments of the colon to achieve 90–95%
sensitivity for the detection of dysplasia.90–93 A reasonable
approach would therefore to perform 4 random biopsies
every 10 cm around the colon. Extra biopsies should be
obtained from strictured or raised areas and from other
abnormal areas in the colon. Full colonoscopy is necessary
because about a third of UC-associated CRC develop in the
proximal colon.85 This strategy is further supported by the
observation that most dysplastic lesions are visible during
careful colonoscopy. In a study performed on 525 patients
who underwent 2204 surveillance colonoscopies, Rutter
detected 110 neoplastic areas in 56 patients.94 Eighty-five
(77.3%) were macroscopically visible at colonoscopy and 25
(22.7%) were macroscopically invisible. Fifty patients
(89.3%) had macroscopically detectable neoplasia, while
only 6 (10.7%) had macroscopically invisible lesions. The
value of random biopsies, however, is limited compared to
optical techniques that enhance detection of dysplastic
epithelium.
71ECCO Consensus on UC: Special situations9.3.2. ChromoendoscopyECCO Statement 9H
Random biopsies (4 every 10 cm) and targeted biopsies of
any visible lesion should be performed during surveillance
colonoscopy [EL2b, RGB]. Methylene blue or indigo carmine
chromoendoscopy is an alternative to random biopsies for
appropriately trained endoscopists and is superior to
random biopsies in the detection rate of neoplastic lesions
[EL1b, RG B]
ECCO Statement 9J
High grade dysplasia in flat mucosa and adenocarcinoma
are indications for proctocolectomy [EL2, RG B]. A patient
with low-grade dysplasia in flat mucosa should be offered
proctocolectomy or repeat surveillance biopsies within 3–
6 months [EL2b, RG B]
ECCO Statement 9K
A raised lesion with dysplasia should be completely resected.
In the absence of dysplasia in the flat surrounding mucosa,
meticulous endoscopic surveillance should be proposedThe yield of surveillance colonoscopy can be improved by
spraying dyes (such as methylene blue or indigo carmine) that
highlight subtle changes in the architecture of the colonic
mucosa.95–101 All studies have confirmed an improved diag-
nostic yield for dysplasia detection using chromoendoscopy.
With this method, random biopsies of apparently normal
mucosa is of no additional value compared to targeted biopsies
obtained after dye staining of the mucosa.101 Comparable
diagnostic yields from chromoendoscopy have been obtained
with both methylene blue and indigo carmine.97,98 Despite
these good results, a single from experienced investigators
found that nodysplasiawasmissedevenwithout dye spraying.94
However, trained endoscopists in chromoendoscopy may even
further distinguish neoplastic from non-neoplastic changes,
based on surface crypt architecture based on pit pattern
recognition with a sensitivity of 93% and 97%, respectively.
Colonoscopy with dye staining did not take significantly longer
than conventional colonoscopy.98 This endoscopic approach
may not only improve the yield of screening and surveillance
colonoscopies, but also decrease the workload of pathologists
because fewer biopsies are needed per procedure.
9.4. Dysplasia
The ultimate goal of surveillance colonoscopy is to identify
whether the colonic mucosa has already undergone the early
steps of malignant transformation (i.e. to detect dysplasia),
which identifies UC patients at the highest risk of CRC
development.102,103 Dysplasia in UC is stratified as low grade,
high grade or indefinite for dysplasia, according to the
presence or absence of specific histological changes in the
epithelium. If biopsies are indefinite for dysplasia and this is
confirmed by an experienced pathologist, then follow-up
surveillance colonoscopy within 3 to 6 months is recom-
mended, with intensification of UC therapy in the meantime.
9.4.1. Risk of progression to cancerECCO Statement 9I
A finding of dysplasia should be confirmed by an independent
pathologist [EL2b, RG B]
[EL2b, RG B]. If endoscopic resection is not possible or if
dysplasia is found in the surrounding flat mucosa,
proctocolectomy should be recommended [EL2b, RG B]The grade of dysplasia is important because it impacts on
the sensitivity and specificity of the presence or future
development of CRC. Dysplasia of any grade has been
reported to have a 74% sensitivity and 74% sensitivity for
CRC development, while in the same series from the MayoClinic, high grade dysplasia had lower sensitivity (34%) but
98% specificity for CRC detection.104 In the most recent
meta-analysis, low-grade dysplasia was found to be asso-
ciated with a 9-fold increased risk of developing CRC and a
12-fold risk of developing advanced neoplasia.105 Therefore,
the finding of low-grade dysplasia carries a substantial risk:
such a finding has important prognostic implications. For this
reason, dysplasia should be confirmed by an experienced
pathologist, because interobserver variation for the detec-
tion of dysplasia is high.106–108 Furthermore, individual
studies that do not show an increased risk of malignant
transformation in low-grade dysplasia109 need to be placed in
the context of the meta-analysis.
9.4.2. Dysplasia and colectomyOnce dysplasia is found, the rationale of such a surveil-
lance programme demands that colectomy is performed,
because the risk of CRC is appreciably increased.105 If high
grade dysplasia is present, the decision is easier, because the
risk of concomitant CRC may be as high as 32%,106 assuming
that the biopsies were indeed obtained from flat mucosa and
not from an adenoma. If low-grade dysplasia is detected, the
9-fold increased risk of developing CRC reported in the most
recent meta-analysis105 could reasonably be viewed as
justification for colectomy as well, and this option should
be discussed with the patient.110 However, because some
follow-up studies of patients with \low-grade dysplasia have
shown a low rate of CRC development,86,111 it seems a
reasonable compromise to continue surveillance with exten-
sive biopsy sampling at shorter (perhaps 3–6 month) intervals
in those who will adhere strictly to the surveillance program.
This remains controversial in the literature and was discussed
during the conference as well.66,112
9.4.3. Dysplasia and raised lesionsRaised lesions on a background of UC have been tradition-
ally referred to as “Dysplasia Associated Lesion or Mass” or
DALM. Until recently this finding has been considered an
absolute indication for colectomy. It is increasingly recognised,
however, that some of these raised lesions may resemble
sporadic adenomas and that they may be amenable to
complete endoscopic resection.97,113–115 If the polypectomy
is confirmed complete by histology and if biopsies obtained
ECCO Statement L
Chemoprevention with 5-ASA compounds may reduce the
incidence of colorectal cancer in UC patients and should
be considered for all UC patients [EL2, RG B]. Colorectal
cancer chemoprevention with ursodeoxycholic acid
should be given to patients with PSC [EL1b, RG B]
72 L. Biancone et al.from the flat mucosa immediately adjacent to the polypect-
omy site show no dysplasia and if, in addition, no dysplasia is
found elsewhere in the colon, then colectomy may be safely
deferred. Careful follow-up, preferably with surveillance
colonoscopy at 3 months and then 6 monthly, is needed if
this strategy is followed, because at least half of such patients
in the four studies quoted developed further raised lesions. If
the lesion does not resemble typical adenoma, is not
respectable, or is associated with dysplasia in the adjacent
mucosa, then colectomy is indicated due to the high risk of
concomitant CRC.90,113
9.5. Chemoprevention
The risk of developing CRC has been shown to be higher in
patients with persistent mucosal inflammation,73 and thus
appropriate therapy may reduce the risk of CRC associated
with chronic UC. Several studies suggest that sulfasalazine or
mesalazine may lead to a risk reduction, referred to as a
chemoprotection. Velayos et al. performed a meta-analysis
that included 334 cases of CRC, 140 cases of dysplasia and a
total of 1932 subjects extracted from 3 cohort studies and 6
case-control studies.79 This suggested that in a population
matched for extent and duration of UC, aminosalicylates
may reduce the risk of colorectal cancer. The risk reduction
was significant for CRC development (OR 0.51, 95% CI 0.37–
0.69), but not for dysplasia (OR 1.18, 95% CI 0.41–3.43). In
view of the low toxicity of mesalazine and considering that
the number of patients needed to treat (NNT) to prevent one
CRCmay be as low as 7 in patients with 30 years of disease,116
the Consensus felt that such a therapy should be considered
and potentially offered to all UC patients in the absence of
contraindications. The limitations of the data are, however,
recognised and some large studies have shown no benefit.78
When 76 cases of CRC and UC in a cohort of 18,969 patients in
the UK General Practice Research Database were compared
to six matched control cases, regular users of 5ASA (defined
as six or more prescriptions in the preceding 12 months) had
a trend towards a lower risk of CRC compared with irregular
uses (unadjusted OR 0.7, 95% CI 0.44–1.03). For mesalazine,
but not sulfasalazine, the effect was significant depending
on the total number of prescriptions: OR 1.13 (0.49–2.59) for
6–12 prescriptions, OR 0.30 (0.11–0.83) for 13–30 prescrip-
tions and OR 0.31 (0.11–0.84) for N30 prescriptions.117
Patients with UC-associated PSC appear to be at particu-
larly high risk of developing CRC.75 In follow-up to a
randomised trial evaluating the benefit of ursodeoxycholic
acid in these patients, patients assigned to active medication
for their biliary disease had a lower incidence of dysplasia
and CRC development compared to patients assigned to
placebo.118 This study confirmed prior data from a cross-
sectional study119 in the setting of a prospective randomised
trial. The Consensus considered these data sufficient
evidence to recommend this therapy in all patients with UC
and PSC, considering the potential benefit of the drug on
both conditions and low toxicity. Nevertheless, the limita-
tions of the data are again recognised, since not all studies
have identified an association between PSC and CRC in
patients with UC.79 Interestingly, when the same group
examined population-based as opposed to hospital-based
cohorts, a significant association between PSC and CRC was
identified (OR 6.9, 95% CI 1.2–40), although a protectiveeffect of aminosailcylates could not be discerned (cumula-
tive dose of sulfasalazine (OR per kg 1.1, 95% CI 1.0–1.3) and
mesalazine (OR per kg 1.3, 95% CI 0.9–1.9).789.6. Prognosis
The prognosis of CRC complicating UC has generally been
considered worse than for sporadic CRC. This may not be
valid. In a report from the Mayo Clinic, 290 patients with IBD-
associated CRC (241 with chronic ulcerative colitis and 49
with Crohn's disease) were matched with an equal number of
age- and sex-matched sporadic CRC patients between 1976
and 1996. 55% of IBD-related tumours were distal to the
splenic flexure compared to 78% of sporadic CRC, but during
a median follow-up period of 5 years, 163 IBD-associated CRC
patients died (56%), compared with 164 sporadic CRC
patients (57%). The 5-year survival rates were 54% in the
IBD-CRC subgroup vs. 53% in the sporadic CRC subgroup
(p=0.94).120 This is not that dissimilar to experience from St
Mark's Hospital. In the largest experience of surveillance
colonoscopy in 600 patients during 5932 patient–years of
follow-up, 30 patients (5%) developed CRC, with a 5-year
survival rate of 73.3%.69
The prognosis of colorectal dysplasia in IBD is also debated
(Section 9.4.1). In a population-based study from Minnesota,
29/725 (4%) IBD patients developed flat dysplasia (n=8), a
Dysplasia Associated Lesion or Mass (DALM, n=1), or an
adenoma-associated lesion or mass (ALM n=18) in an area of
IBD, or an ALM outside the area of IBD (n=2). Among 6
patients with flat low-grade dysplasia (fLGD) who did not
undergo colectomy, none progressed during a median of 17.8
(range 6–21) years of observation with a median of 3 (range
0–12) surveillance colonoscopies. Four (22%) patients with
ALMs in areas of IBD who did not undergo surgery developed
low-grade dysplasia or DALMs. Dysplasia located proximal to
the splenic flexure was significantly associated with a risk of
recurrence or progression of dysplasia. This population-
based cohort did not confirm an increased risk of cancer
related to flat low-grade dysplasia,78 which is at odds with
the meta-analysis.105
10. Children and adolescents
10.1. Introduction
About 10–15% of patients with inflammatory bowel disease
are diagnosed before the age of 18 years.121 During puberty
the incidence is 7 per 100 000 per year and increases further
during adolescence to about 12 per 100 000 at age 20–29,
consistent with a peak around the age of 30 years.122 In
children most cohort studies show a lower incidence of
ulcerative colitis (UC) compared to Crohn's disease (CD),123
but the incidence of CD has clearly increased over the past
ECCO Statement 10C
Ileocolonoscopy and biopsies should be performed in all
children or adolescents with a suspicion of inflammatory
bowel disease (IBD). Upper gastrointestinal endoscopy is
recommended when ileocolonoscopy does not confirm a
diagnosis of ulcerative colitis [EL2a, RG B]
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studies,124–126 but increasing in other cohorts.127–129 The
median age of onset of symptoms in UC is 12 years in most
paediatric studies,122,130,131 but the diagnostic delay is
considerably shorter than for CD. In contrast to adults, the
clinical presentation of UC is often more severe in children,
which may be explained by the predominance of pancolitis
(70–80% of children) at the time of diagnosis.131,132
10.2. Diagnosis
10.2.1. Diagnostic thresholdECCO Statement 10A
Ulcerative colitis should be suspected in a childwith chronic
(≥4 weeks) or recurrent (≥2 episodes in 6 months) bloody
diarrhoea, after exclusion of infective or other causes. This
applies particularly when there is growth failure and/or
pubertal delay, a family history of IBD, increasedmarkers of
inflammation, or if anaemia is present [EL2b, RG B]
ECCO Statement 10D
In children and adolescents (up to 16–18 years of age),
endoscopy should be performed by a specialist with
experience in paediatric gastroenterology, preferably by a
paediatric gastroenterologist [EL 5, RG D], in a setting that
is suitable for diagnosing and treating children with IBD
(paediatric hospital, with access to general anaesthesia)In contrast to paediatric CD and its diverse symptomatol-
ogy, the clinical manifestation of UC is almost uniformly
bloody diarrhoea (84–94% of children), accompanied by
tenesmus.132 Although an infective aetiology should be
excluded, its presence does not exclude a diagnosis of UC
or CD. The combination of rectal bleeding, anaemia and
increased ESR identified 86% of patients with IBD prior to an
endoscopic procedure.133 Other retrospective case series
have confirmed the diagnostic value of increased inflamma-
tory markers and anaemia for IBD.134,135
A shorter interval from symptoms to diagnosis of UC
probably explains why growth failure is half as common
compared to CD. As with adults, the greatest risk factor for
developing UC in childhood is to have a family member with
ulcerative colitis (relative risk 7–17).137,138 The risk for CD in
a family member with Crohn's disease is a relative risk of 15–
35. The stronger the family history, the earlier the onset of
symptoms. For patients with early-onset UC (b5 years' age),
26%–44% have a family history of UC, compared to older
patients or children with CD.139,140 Genetic factors are likely
to have a stronger influence in paediatric IBD, especially in
early-onset acute severe UC, compared to older children or
adults.141,142 Nevertheless, most children with IBD have no
family history and are considered sporadic.
10.2.2. DocumentationECCO Statement 10B
In all childrenwithUC, the height,weight (andpre-diagnosis
growth curve) and pubertal stage, should be recorded at
diagnosis, and regularly during follow-up [EL3b, RG B]
ECCO Statement 10E
Oral [EL2b,RGB] aminosalicylates and/or topical
aminosalicylates (suppositories in proctitis, enemas in
left-sided colitis) [EL5, RGD] are appropriate initial
induction therapy for mild to moderate distal colitis in
children or adolescentsGrowth failure is a unique complication of paediatric IBD,
caused by a combination of inadequate calorie intake, increased
losses and active inflammation. Efficacy of medical treatment
and concomitant mucosal remission is characterised by normal
linear growth and pubertal development. In contrast, when
catch-up growth does not occur after growth failure atdiagnosis, or when height velocity decreases during mainte-
nance treatment, it is highly likely that there is persistent
disease activity, so therapy should be more aggressive and an
adequate calorie intake ensured.136,143,144
10.2.3. Diagnostic proceduresThe IBD working group of the European Society of Paediatric
Gastroenterology Hepatology and Nutrition (ESPGHAN) has
reached a consensus on the diagnosis of IBD in children, which
has been summarised in the ‘Porto Criteria’.145 This group feels
it essential to establish a diagnosis of the type of disease, aswell
as to determine severity, localisation, andextent of thedisease,
before treatment is started. Paediatric patients with UC have
more extensive disease and rectal sparing in up to 30%,146 so a
complete diagnostic work-up is warranted in children with
bloody diarrhoea. Evidence supporting colonoscopy with ileal
intubation and multiple biopsies, rather than sigmoidoscopy
alone, is provided by retrospective cohort studies.146–148 In
cases with extensive colitis that cannot be classified, gastro-
duodenoscopy may allow definitive diagnosis.149
The ECCO Consensus agrees that a paediatric gastroenter-
ologist, rather than a specialist in adult endoscopy, should best
perform endoscopy in children suspected of IBD. The most
important argument is quality of care, particularly because
endoscopy in children is preferably done under general
anaesthesia: this is preferred for reasons of comfort and care
and has been shown to be safe.150–155 Moreover, the treatment
and follow-up of children and adolescentswith IBD should be in
the hands of a paediatric gastroenterologist who is aware of
age-related differences in disease presentation and treat-
ment. Such specialists are experienced in handling problems
such as linear growth retardation and pubertal delay.156
10.3. Induction therapy in children
10.3.1. Distal colitis
ECCO Statement 10G
For severe pancolitis in children, corticosteroids are first
line therapy [EL4, RG D]. If the response is insufficient,
intravenous ciclosporin [EL4, RG C] or infliximab [EL4, RG
C], or colectomy are appropriate options
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colitis. A questionnaire sent to members of the IBD working
group of ESPGHAN, however, revealed great variation of care
in the treatment of distal colitis. The first choice was either
oral treatment alone (mesalazine 21%, sulfasalazine 36%), or
in combination with topical treatment (mesalazine 36%,
corticosteroids 7%). Considering the rarity of proctitis in
children, no standard treatment protocols exist.
10.3.2. Extensive colitisECCO Statement 10F
For mild to moderate pancolitis in children, oral
mesalazine/sulfasalazine is recommended as first line
therapy [EL2b, RG B]. Oral steroids are appropriate if the
response is insufficient [EL4, RG D]Only one prospective study has confirmed the efficacy of
oral aminosalicylates in children with active ulcerative
colitis.157 In this trial, a clinical response at 8 weeks was
seen in 79% of patients receiving sulfasalazine (60 mg/kg/
day) and 50% of patients on olsalazine (30 mg/kg/day).
Retrospective studies have also shown that oral aminosali-
cylates effectively induce clinical remission.158–162
Although sulfasalazine may cause more gastrointestinal
side-effects, it is the preferred aminosalicylate treatment in
young children who cannot swallow tablets, because it is
available as a suspension. Alternatively, mesalazine can be
given as an enteric-coated granule formulation. Based on
expert opinion and extrapolation from pharmacokinetic
studies,159,161,163 the advised dose (oral and rectal mesalazine
combined) in children aged 12 years or older of mesalazine, is
50–75 mg/kg/day with a maximum of 4 g/day. For sulfasala-
zine it is 100 mg/kg/day with a maximum of 6 g/day.
Concerning oral corticosteroids, no studies have been
performed in children with UC. Nevertheless, prospectively
collected data from the US Pediatric Inflammatory Bowel
Disease Collaborative Research Group Registry database
provides a useful insight.164 In 97 children (age b16 yr) with
newly diagnosed UC between 2002 and 2005, with a minimum
of 1 year of follow-up, 79% received corticosteroids, most
(62/77) within 30 days of diagnosis. For those treated within
30 days, disease activity at 3months was inactive in 60%,mild
in 27%, and moderate or severe in 11%. At 12 months, 31 of 62
(50%) of the early corticosteroid-treated patients were
considered corticosteroid responsive and 28 (45%) were
corticosteroid-dependent. A total of 4 patients receiving
corticosteroids required colectomy in the first year. Immu-
nomodulators were used in 61% of all corticosteroid-treated
patients. This is similar to adults: early response is excellent,
but dependence is common, even with immunomodulators.
Evaluation among the IBD working group of ESPGHAN
demonstrated that 46% favoured addition of corticosteroids
if response to aminosalicylates was found to be insufficient.
Oral prednisolone is given as a once daily dose of 1–2 mg/kg/
day, with a maximum dose of 40 mg, for 2–4 weeks (until
clinical remission), then tapered to zero in 6–8 weeks.
Although not supported by clinical evidence from randomised
clinical trials, calcium and vitamin D are usually supplemen-
ted during a course of steroid treatment.10.3.3. Severe colitisAlthough no randomised clinical studies have been per-
formed in childrenwith acute severeUC, all respondents to the
ESPGHAN questionnaire agreed that corticosteroids are the
first line therapy in severe pancolitis. In a meta-regression of
response to steroids in 32 studies involving 1991 patients
(1974–2006), only 43 children were included.165 To evaluate
the outcome in children, a retrospective study of 74 admissions
in 63 children (57% males, age at diagnosis 10.9±4 yr, 79%
extensive colitis) treated at Toronto SickKids Hospital 1995–99
was performed.166 41% failed intravenous steroids by discharge
and 23 (37%) came to colectomy on that admission. By one
year, 54% and by 5 yr 59% had come to colectomy. There was no
clear consensus from ESPGHAN as to whether corticosteroids
should be given as the only treatment (25% of respondents), or
in combination with oral mesalazine (25%), or intravenously
with adjunctive parenteral nutrition (50%). Given the similar-
ity in the response of children to steroids compared to adults
(Section 5.2.4, preceding paper same issue), it seems unlikely
that mesalazine is necessary. Although nutritional support is
particularly appropriate in children, TPN in adults has not been
shown to offer any advantage when managing acute severe
colitis (Section 5.2.4, preceding paper same issue).
When 3–5 days of intravenous corticosteroids are inef-
fective, rescue therapy with ciclosporin, tacrolimus, or
infliximab are the only two options to avoid or postpone
colectomy. An objective assessment of the response to
steroids facilitates management as it does in adults (see
Section 5.2.5, preceding paper same issue). A paediatric
index of severity as been developed166 and when calculated
on day 3, strongly predicts failure of intravenous steroids.167
As with adults, stool frequency (p=0.001) and CRP (p=0.045)
on day 3 (but not day 1) predict failure, along with
temperature (p=0.001). Case studies with intravenous
ciclosporin in children with severe, steroid-refractory colitis
who are candidates for surgery, have shown remission of the
disease in up to 80% of cases.168–172 In many children,
however, tapering of oral ciclosporin resulted in a relapse
and was followed by colectomy within a year of cessation of
treatment. In occasional patients, short term ciclosporin
treatment can effectively induce remission while waiting for
azathioprine maintenance treatment to take effect.170
Infliximab has not been studied prospectively, but small
retrospective studies in new-onset steroid-refractory patients
show complete remission in 75–88% of patients.173–175 With
the small numbers of patients studied and limited follow-up, it
is currently unknownwhether infliximab therapy is effective in
avoiding colectomy, or whether it simply defers it. The
Consensus view is that rescue therapy with either ciclosporin,
tacrolimus, or infliximab should only be initiated in a specialist
centre where a paediatric and/or colorectal surgeon are
available and involved in the treatment of these severely sick
children.
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Oral mesalazine or sulfasalazine are recommended
maintenance treatment in the same dose as for induction
therapy [EL5, RG D]. For difficult patients with extended
and/or relapsing disease, who are steroid-refractory or
steroid-dependent, azathioprine/mercaptopurine is
recommended [EL4, RG C]. Long-term steroids are
contraindicated and ciclosporin is inappropriate ECCO Statement 10J
Colectomy should be performed by an experienced
paediatric surgeon, ideally with the assistance of a
colorectal surgeon with paediatric experience; ileo-
pouch-anal anastomosis (IPAA) should only be performed
in a highly specialised centre [EL 4, RG C]
ECCO Statement 10K
Enteral or parenteral nutritional therapy is inappropriate
primary treatment. However, a nutritional evaluation is
essential and nutritional support should be provided when
required [EL5, RG D]
ECCO Statement 10L10.4.1. Aminosalicylates
The efficacy of mesalazine or sulfasalazine maintenance
treatment has not been studied in children with UC. From the
IBD working group of ESPGHAN questionnaire respondents,
57% advised continuing the same mesalazine dose as used for
induction, while 43% advised a lower dose. The Consensus
view is based on results from adult studies that indicate that
high dose 5-ASA is effective maintenance treatment. Long-
term corticosteroids are absolutely contraindicated, because
they do not maintain remission and have a negative effect on
linear growth and bone mineralisation. Ciclosporin main-
tenance treatment is ineffective and inappropriate, because
serious, sometimes irreversible, side-effects may occur.
10.4.2. Thiopurines
Retrospective cohort studies have demonstrated that main-
tenance with azathioprine/mercaptopurine is effective, while
achieving a steroid-sparing effect.176–179 This steroid-sparing
effect is more evident when azathioprine treatment is started
early in the course of disease, within 2 years after diagnosis.179
The advised dose for azathioprine in children is 2–3mg/kg/day
and that for mercaptopurine is 1–1.5 mg/kg/day.
10.5. Surgery in childrenECCO Statement 10I
Colectomy is indicated for severe colitis with acute
complications not responding to medical therapy;
persistently active disease with failure or toxicity of
medical treatment; failure to taper corticosteroid
treatment despite immunosupressant use; growth
retardation or pubertal delay despite medical
treatment [EL 4, RG C]
There is no indication for a “special diet” for ulcerative
colitis, because none are effective and there is a risk of
nutritional deficiencies [EL5, RG D]
ECCO Statement 10M
Psychosocial support is important adjunctive treatment,
because depressive symptoms are frequent and
psychosocial support may be associated with a better
outcome and a better quality of life [EL3b, RG B]10.5.1. Indications
In acute severe colitis, the decision to perform colectomy
should be evaluated on a day-to-day basis by both the medical
and surgical team. If the disease is not responding to 7–10 days
of either calcineurin inhibitors (ciclosporin, tacrolimus) or
infliximab, colectomy is indicated.
Colectomy is also indicated for persistently active disease,
when corticosteroid dependency exists despite concomitant
therapy with azathioprine/mercaptopurine, or when immu-
nosuppressive treatment has side-effects. Growth failure
despite apparently adequate maintenance therapy is also an
indication for colectomy, even when clinical symptoms appearmild.180–184 Preliminary (and anecdotal) experience with
infliximab in children suggests that it may be more effective
in acutely ill patients, compared to patients with chronic
refractory disease.173,175,185 It rarely achieves steroid-free
remission. Therefore, infliximab cannot be recommended
for chronic steroid-dependent disease in children.
10.5.2. ProceduresDepending on the local circumstances, a child needing
colectomy should be referred for expert care at a specialist
centre. Case series of IPAA in children show good results in
terms of quality of life, continence and incidence of
pouchitis.181,182,186–189 However, in very young children
(b10 years), pouchitis is reported in 75% of the patients.190
Because IPAA decreases female fecundity,191,192 colectomy
with ileorectal anastomosis until later IPAA may be a better
option in girls.193 Expert advice should be sought.
10.6. Nutritional supportIt has not been shown that enteral nutrition has a primary
therapeutic role in ulcerative colitis. There are many theories
that suggest that diet may be implicated in the aetiology of
inflammatory bowel disease. However, there is, as yet, no
dietary approach proven to reduce the risk of developing IBD.
Children with IBD have increased calorie and protein require-
ments, so intake should be at least 120% of recommended daily
allowances (RDA). If oral intake is poor due to anorexia during a
period of disease activity, high-calorie supplements may be
indicated and specialist dietetic advice is appropriate.
10.7. Psychosocial support
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developing behavioural difficulties or emotional dysfunction
and depression in particular (in almost 25% of patients), as
well as anxiety, social dysfunction and low self-esteem
compared to healthy children.194–197 The quality of life in
adolescents with IBD is generally lower than healthy
controls.198–201 Two large randomised studies have demon-
strated that psychosocial support by a patient-orientated
self-management approach can have a beneficial influence
on the course of disease.202,203 Therefore, appropriate
medical information and mental health support are recom-
mended, because this may influence disease activity.195
10.8. Transition of care to adult servicesECCO Statement 10N
Transitional clinics represent optimal care and are highly
recommended [EL5, RG D]
ECCO Statement 12A
A speculated association between psychological factors and
the aetiology of ulcerative colitis cannot be proven. There
is, however, an influence of psychological distress andmood
disorders on the course of the disease [EL1b, RG B]
ECCO Statement 12B
There is evidence of an interaction between psychological
factors and IBD activity. Depression and perceived chronic
distress represent risk factors for relapse of the disease. It
remains controversial whether acute life events trigger
relapses [EL 1b, RG B]. Most patients consider stress to
have an influence on their illness [EL 4, RG C]
ECCO Statement 12C
Psychological disturbances seem to be a consequence of the
illness rather than thecauseof, or specific toulcerative colitis.
The degree of psychological distress and disturbances
correlates with the disease severity, predicts health-relatedA careful transition of patients from the paediatric service to
adult gastroenterologists is vital, because it may reinforce
treatment adherence and improve quality of life.204 There are
many differences between paediatric and adult care. In the
paediatric service, children and adolescents with IBD are usually
seen together with their parents and often receive more
attention, because the disease is uncommon in children
compared to adults. A paediatric specialist nurse may be on
hand to advise and be a point of contact for the child or parents.
Endoscopy is performed under general anaesthesia, whereas this
is exceptional in adults. On the other hand, the paediatric
gastroenterologist rarely discusses long-term issues, such as
cancer risk or surveillance. Close collaboration between the
paediatric and adult services will overcome these differences.
The ideal setting for this is a transitional clinic where adolescent
patients are seen by both specialists.205 The alternative is to
establish a parallel clinic, where paediatric and adult IBD clinics
run independently but at the same time, so that when a suitable
patient is seen, it is then a simple matter for the paediatric or
adult gastroenterologist to go down the corridor to contact their
opposite number so that the young person can be introduced or
seen together. A trained IBD nurse specialist can play an
important role coordinating care between the service, the
patient and the family during the transitional period.
11. Pregnancy
The section on pregnancy and ulcerative colitis will be
published subsequently. Theprinciples ofmanaging pregnancy,
delivery, breast-feeding and Crohn's disease also apply to
ulcerative colitis.206 See also Cornish J, Tan E, Teare J, et al. A
meta-analysis on the influence of inflammatory bowel disease
on pregnancy. Gut 2007;56:830–7.
12. Psychosomatics
12.1. Introduction
While psychosocial factors are generally considered important in
ulcerative colitis, controversy still exists about their role. This
leads to potential inconsistencies in clinical practice. A
biopsychosocial model207,208 represents an advantage over abiomedical model, because it embodies the complex biological
and psychosocial interactions that explain human illness or its
effects. Attention to psychosocial factors associated with
ulcerative colitis may have consequences not only on psychoso-
cial well-being and quality of life, but also on the activity of the
disease itself. The key words used in the systematic literature
review of Medline and Embase for this review were ulcerative
colitis as well as inflammatory bowel disease and irritable bowel
syndrome— psychology; psychosocial; psychotherapy; quality of
life; doctor patient relationship; and psychopharmaceuticals.
12.2. Influence of psychological factors on disease
12.2.1. AetiologyStudies about the influence of psychological factors on the
development of ulcerative colitis are very limited. There are a few
studies with hypothetical interpretations about the influence of
psychosocial factors on the aetiology of the disease.209–212 Many
studiesonpsychosocial factors relateto inflammatoryboweldisease
(IBD) rather than ulcerative colitis or Crohn's disease in particular.
12.2.2. Pattern of diseasePsychological factors are considered to have an influence on
the course of the disease, which is consistent with evidence in
the recent literature about the influence of subjective
perceived psychological distress on disease activity of ulcerative
colitis.213–217 Studies about the influence ofmajor life events on
the biological disease activity have yielded contradictory
results.218–220 Patients themselves and themajority of European
experts at the Consensus conference consider psychosocial
distress as influencing the risk of relapse.221,222 One study shows
a heightened response to stressors and the greater epithelial
damage in IBD patients, which suggests that stress-induced
activation of the brain-gut axis and ofmucosalmast cellsmay be
important in the initiation and/or flare up of IBD.223
12.3. Psychological disturbances in ulcerative colitisqualityof lifeand influences thecourseofdisease [EL1b,RGB]
ECCO Statement 12D
Clinicians should particularly assess depression among their
patients with active disease and those with abdominal pain
in remission [EL 2b, RG B]
ECCO Statement 12F
Physicians should assess the patient's psychosocial status,
quality of life and demand for additional psychological care
and recommend psychotherapy if indicated. Integrated
psychosomatic and gastroenterology care should be
available [EL 2b, RG B]. Patients should be informed of the
existence of patient associations [EL 5, RG D]
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only slightly more, psychological disturbances compared to
patients with other chronic diseases.211,224–229 A consistent
association between psychological factors and the preva-
lence of IBS-like symptoms in patients in remission has been
reported.229–232 There is also evidence that children and
adolescents with IBD comprise a population at high risk of
developing a psychiatric disorder.233,234 A recent study with a
large IBD population has shown that IBD patients experience
a rate of depression that is triple that of the general
population (16.3% vs. 5.6%).235 In this study 17% of depressed
patients had considered suicide in the past 12 months and an
additional 30% had considered suicide at an earlier time. In
individuals who were currently depressed, female patients
were more likely than males ever to have considered suicide
(50% vs. 31%). Depressive coping strategies are positively
associated and predict health-related quality of life.236
Furthermore, the psychosocial consequences of the illness
become more significant with increasing severity of the
disease and quality of life is related to disease activity,
symptoms 218,224,237–243 and female gender.237,244,245
12.4. Approach to psychological disorders
12.4.1. Communication with patientsECCO Statement 12E
The psychosocial consequences and health-related quality
of life of patients should be taken into account in clinical
practice at regular visits. Individual information and
explanation about the disease should be provided through
a personal interview. The course of the disease can be
improved by combining self-management and patient-
centred consultations [EL 1b and 3b, RG B]
ECCO Statement 12G
Psychotherapeutic interventions are indicated for
psychological disorders associated with ulcerative colitis
[EL 1b, RG B]Health perceptions impact on the experience of the
illness.226 Increasing physician awareness of the fact that
psychologically distressed patients have difficulty in proces-
sing clinically relevant information 246 may lead to improved
doctor–patient communication.247 It is important that
patients are informed about their condition through an
individual interview, in conjunction with emotional support.
This is because a lower level of information is associated with
greater concern,248 despite the impression of some doctors
that more information increases the level of anxiety.
Psychosocial factors are strongly correlated with health
care utilization.249 Self-management guidebooks together
with patient-centred consultations improve patients' disease
control.250,251 It should however be recognised that educa-
tional booklets on their own do not seem to be helpful and
may even worsen the health-related quality of life of
patients attending tertiary centres.252 In addition, patient
education programmes seem to have very limited or even no
influence on the course of their illness, their health-related
quality of life, or their psychological affect.253–255 Almost allexperts at the Consensus (91%) are convinced that a good
doctor–patient relationship is helpful psychologically and
take psychosocial factors into account for both diagnosis and
therapy. Most experts at tertiary centres have the opportu-
nity for integrated somatic and psychological care of
patients. However, patients describe deficiencies in the
care of family members, insufficient information and
inadequate access to healthcare resources.256
12.4.2. Psychological supportFor assessment of quality of life, two validated IBD-specific
questionnaires have been shown to be sensitive, reproducible
and responsive for use in clinical trials: the Inflammatory
Bowel Disease Questionnaire (IBDQ)257 and the Rating Form of
Inflammatory Bowel Disease Patient Concerns (RFIPC).258
Detection and treatment of psychological distress has the
potential to improve health-related quality of life.259 The
presence of psychological disorders contributes to poor quality
of life and the number of doctor visits, regardless of the
severity of the condition.249 This is the common experience of
doctors caring for patients with IBD, even if the potential or
need to treat this aspect of the illness is perceived.
To assess the demand for psychological care in chronic
diseases, a validated questionnaire is available, developed
and based on inflammatory bowel disease.260 Most experts
(80%) feel themselves able to recommend psychotherapy
during a discussion with patients. There is no study on their
competence at doing this, but this is consistent with the
experience of participants in the European Consensus on the
management of Crohn's disease,206 the German Consensus on
Crohn's disease,56 and that on ulcerative colitis.261,262 Since
strategies aimed at improving social support can have a
favourable impact on psychological distress,263 training of
gastroenterologists to integrate psychosocial factors in
clinical practice should be taken into consideration.
12.4.3. Therapeutic interventionPsychotherapy and relaxation methods have a positive
influence on IBD, mainly affecting the psychological dimen-
sions of the illness such as psychological well-being, coping
strategies and psychological distress,264–268 as well as
perception of pain.269 This underpins the recommendation
(Statement 12G). The diagnosis of ulcerative colitis is
insufficient alone to recommend psychotherapy, since
studies of psychotherapy on patients without psychological
78 L. Biancone et al.disturbance show little or no benefit.270 One study that
combined patients with Crohn's disease and ulcerative colitis
reported an influence of psychotherapy on disease activity,
but there was inhomogeneity in randomisation of the
treatment and control groups, so the results are not included
in the evidence-based recommendation.
12.4.4. Therapeutic choiceECCO Statement 12G
The choice of psychotherapeutic method depends on the
psychological disturbance and should best be made by
specialists (Psychotherapist, Specialist for Psychosomatic
Medicine, Psychiatrist). Psychopharmaceuticals should be
prescribed for defined indications [EL 5, RG D]
ECCO Statement 13A
Diagnosis of non-axial arthritis and arthropathy associated
with UC ismade on clinical grounds based on characteristic
features and exclusion of other specific forms of arthritis
[EL3b, RG C]. Type I is pauciarticular and affects large joints
acutely at times of UC activity. Type II is polyarticular,
affecting a larger number of peripheral joints independently
of UC activity [EL 2b, RG B] Axial arthritis, including sacro-
iliitis and ankylosing spondylitis, is diagnosedon conventional
rheumatological grounds, and is supported by characteristic
radiological changes, magnetic resonance imaging being the
most sensitive [EL2b, RG B]. Although HLA B-27 is over-
represented in axial arthritis related to UC this is not of
diagnostic value [EL2b, RG B]There is no evidence that one psychotherapeutic method
should be preferred over another. Relaxation exercises are
useful, since they are easy to learn and perform. Expert
opinion believes that there is an advantage if the psy-
chotherapist has experience in the treatment of patients
with chronic inflammatory bowel diseases and works closely
with the patient's gastroenterologist. There are no specific
studies on the use of individual psychopharmaceuticals in
ulcerative colitis.271 In spite of this, almost all experts
believe that there are clinical situations in which antide-
pressants should be recommended for treatment of psycho-
logical distress associated with ulcerative colitis.
13. Extraintestinal manifestations
13.1. Introduction
Extra-intestinal manifestations (EIMs) occur in up to 30% of
patients affectedbyulcerative colitis or Crohn's disease,272–274
although it is probable that studies from referral centres have
over-estimated the prevalence and community studies suggest
that their prevalencemay bemuch lower.What is interesting is
that the occurrence of one EIM appears to predispose to
others. This suggests an underlying generic susceptibility in
some patients that is largely genetically determined, although
may yet be prone to environmental influence. Female patients
with colitis (either ulcerative or Crohn's colitis) appear to be
particularly susceptible.275
Scoring systems such as the Crohn's disease activity index
(CDAI) include EIMs in the assessment. This is a weakness,
although not widely recognised, since only some EIMs are
related to disease activity and a genetic susceptibility in a
minority of patients introduces bias. Those EIMs broadly
related to the activity of colitis include oligoarticular
peripheral arthritis, erythema nodosum, oral aphthous ulcers
and episcleritis.274 Polyarticular peripheral arthritis, pyo-
derma gangrenosum [PG], uveitis and spondylarthropathy
tend to pursue a course independent of disease activity, while
primary sclerosing cholangitis [PSC] is most prevalent in
patients with colitis that follows an apparently mild course.
For those EIMs closely related to ulcerative colitis activity,
treatment can parallel that of the underlying disease.
Treatment otherwise is mainly on a case-by-case basis as
randomised controlled trials are mostly lacking. Specifictherapy for EIMs is strongly influenced by current IBD
treatment, and may include increasing dosage of existing
drugs or the addition of new agents.
Consensus review indicates that gastroenterologists will
be comfortable diagnosing and treating the more common
extraintestinal manifestations, unless they prove resistant,
with the exception of eye involvement for which the advice
of an ophthalmologist is selected in a great majority of cases
(93%). It is noted however that the frequency with which
routine dermatological (46%) and rheumatological (31%)
advice would be sought has increased since the review
panel was interrogated on their approach to EIMs of Crohn's
disease in 2004.206 This section concentrates on the more
frequently encountered EIMs, for which at least some
quantifiable data exist. Thrombotic complications of colitis
and their prevention are considered in the section on acute
management of colitis. Anaemia in colitis (as in Crohn's
disease) is too frequently neglected: authorative guidelines
have been published separately.276
13.2. ArthropathiesThe diagnosis of non-axial arthritis and arthropathy
associated with inflammatory bowel disease (IBD) is made
on clinical grounds and t types have been defined by the
Oxford group. The distinction is supported by differences in
genetic susceptibility.277 Type I is a large joint pauciarticular
arthropathy that occurs at times of IBD activity, while type II
is a polyarticular small joint arthropathy, whose activity is
largely independent of IBD activity. Axial arthritis includes
sacroiliitis and ankylosing spondylitis which are diagnosed
clinically, supported by characteristic radiological changes.
Magnetic resonance imaging is the diagnostic tool of choice.
13.2.1. Pauciarticular peripheral arthropathy
Type I arthropathy277 predominantly affects weight-bearing
joints, including the ankles, knees, hips, wrists, elbows and
shoulders. Pauciarticular means that fewer than five joints
are affected. The arthritis is usually acute, self-limiting,
resolves within weeks as disease activity decreases, and
leaves no permanent joint damage. Clinical examination
reveals painful, tender, swollen joints. Aspiration is unne-
cessary unless an alternative diagnosis is suspected. The
differential diagnosis includes osteoarthritis, septic arthritis,
pyrophosphate arthropathy, coincidental rheumatoid
ECCO Statement 13C
Diagnosis of the cutaneous manifestations of UC is made
on clinical grounds, based on their characteristic features
and (to some extent) the exclusion of other specific skin
disorders; biopsy is rarely appropriate or necessary [EL3b,
RG C]
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then steroid-induced osteonecrosis should be considered.279
13.2.2. Polyarticular peripheral arthropathy
Type II arthritis predominantly affects the small joints of
both hands as a symmetrical arthropathy. Pain is commonly
disproportionate to the signs of arthritis. It usually persists
for months or years and follows a course independent of IBD
activity. It may persist after colectomy or start after ileo-
pouch-anal anastomosis. The differential diagnosis includes
osteoarthritis, but also includes treatment side-effects such
as steroid-induced pseudorheumatism (which is common
after withdrawal of long-term steroids) and mesalazine- or
azathioprine-induced arthropathy.278
13.2.3. Axial arthropathy
Asymptomatic sacroiliitis is common, with up to 50% of colitis
patients having abnormal radiography.279 Symptomatic
sacroiliitis is characterised by pain in the buttocks after
rest, which then improves with movement. The clinical sign
of discomfort in the sacroiliac joints during bilateral pressure
on the pelvic brim is indicative. The principal symptom of
ankylosing spondylitis is persistent low back pain, usually
beginning before the age of 30. Clinical examination reveals
loss of the lumbar lordosis and limited spinal flexion.
Conventional radiographs of the back are usually normal in
the early stages of disease. Spinal CT scans and radionuclide
bone scans are more sensitive than plain radiographs, but the
gold standard is now magnetic resonance imaging
(MRI).280,281 There is however an impression that minor
abnormalities of little or no clinical consequence may be
seen on MRI; this remains to be determined by longer-term
follow-up. In advanced cases there may be squaring of the
vertebral bodies, marginal syndesmophytes and bony pro-
liferation, with ankylosis producing the classical “bamboo
spine”. HLA B-27 associations is found in a majority (up to
75%) of patients with axial arthritis, but is less common than
in patients with ankylosing spondylitis not associated with
IBD. It is unrelated to sacroiliitis and HLA typing has no role in
the management of individual patient.282,283
13.2.4. Therapy of arthropathiesECCO Statement 13B
Treatment of arthritis and arthropathy associated with UC
is based almost entirely on extrapolation from that for
other forms of arthritis. There is some support for use of
sulfasalazine, simple analgesics, non-steroidal anti-
inflammatory agents, local steroid injections, and
physiotherapy [EL4, RG D]. In Type I peripheral arthritis
the emphasis should be on that of the underlying colitis
[EL2c, RG C]. In axial arthritis the arguments in favour of
intensive physiotherapy [EL2a, RG B], sulfasalazine [EL2a,
RG C], methotrexate [EL3b, RG C], and infliximab [EL2a,
RG C], are somewhat strongerTreatment of arthritis and arthropathy associated with
IBD is largely empirical. This includes the use of simple
analgesics, sulfasalazine, local steroid injections and phy-
siotherapy, but whether or not to use non-steroidal anti-inflammatory agents is a continuing dilemma, even though
short term use appears not to exacerbate colitis.284
For Type I peripheral arthritis the emphasis should be on
the treatment of active disease, including steroids, immu-
nomodulation, and anti-TNF therapy as appropriate. Resolu-
tion of the arthropathy can be expected. The joint-specific
drug of first choice for all forms of IBD-related arthritis
appears to be sulfasalazine, but convincing evidence to
support this is lacking. Nevertheless, it was favoured by the
greatest minority of panel members (41%). Symptomatic
relief may be obtained from simple analgesics, rest and
physiotherapy.279,284,285,286 Although there is concern that
non-steroidal anti-inflammatory agents (conventional and
COX II inhibitors) may aggravate the underlying colitis,287,288
they have been used by many gastroenterologists to good
effect with limited risk of exacerbating colitis. A previous
history of flare related to NSAID intake seems to be the best
indicator of individual risk. A randomised study of the safety
of celecoxib in colitis283 indicated that short-term use
(b2 weeks) did not exacerbate colitis. Local steroid injection
into the worst-affected joints often provides rapid, but
temporary relief. Type II arthritis generally resolves with
effective treatment of the colitis.289
Treatment of axial arthritis should include intensive
physiotherapy, together with disease modifying drugs such
as sulfasalazine, andmethotrexate.279,285,289 The safety and
efficacy of infliximab in ankylosing spondylitis is estab-
lished, but is best reserved for intractable or severely
debilitating symptoms.290,291 This is because of the 15%
prevalence of immunogenicity and the small, but definable
risk of notable adverse events such as sepsis, tuberculosis, or
demyelination.
13.3. Cutaneous manifestations13.3.1. Erythema nodosum
Erythema nodosum is usually readily recognised. It is
characterised by raised, tender, red or violet subcutaneous
nodules of 1 to 5 cm in diameter. It commonly affects the
extensor surfaces of the extremities, particularly the
anterior tibial area, and usually occurs at times of activity
of the colitis. A firm clinical diagnosis can normally be made,
and biopsy is not normally appropriate. If performed, the
histology reveals a non-specific focal panniculitis.292,293
Because erythema nodosum is closely related to disease
activity, despite a genetic link,294 treatment is based on that
of the underlying colitis. Systemic steroids are usually
required (76% Consensus view). In resistant cases or when
there are frequent relapses, immunomodulation with
azathioprine and/or infliximab may be added, but it is
exceptional to need such measures just because of erythema
nodosum. Oral potassium iodide has been used successfully in
refractory cases.295
80 L. Biancone et al.13.3.2. Pyoderma gangrenosum (PG)
Lesions are often preceded by trauma at the site (which may
have beenmany years earlier) through a phenomenon known
as pathergy. PG can occur anywhere on the body, including
the genitalia, but the commonest sites are the shins and
adjacent to stomas. Initially they take the form of single or
multiple erythematous papules or pustules, but subsequent
necrosis of the dermis leads to the development of deep
excavating ulcerations that contain purulentmaterial that is
sterile on culture unless secondary infection has occurred.
Treatment of pyoderma gangrenosum has relied on
topical and systemic steroids. Steroids were considered
the most effective treatment for pyoderma gangrenosum
(54% Consensus view), with intravenous ciclosporin or
tacrolimus reserved for refractory cases.296–298 There are,
however, no reliable trials to support the use of high dose
steroids or calcineurin inhibitors and these drugs have
appreciable potential side-effects. Infliximab has changed
the management of PG. In the first controlled trial in
pyoderma (which also included patients without IBD)
infliximab 5 mg/kg or placebo was given at week 0.299 At
week 2 (the primary end point), significantly more patients
in the infliximab group had improved (46% (6/13)) compared
with the placebo group (6% (1/17), p=0.025). Overall, 29
patients received infliximab with 69% (20/29) demonstrat-
ing a beneficial clinical response. Remission at week 6 was
21% (6/29). There was no response in 31% (9/29) of patients.
Infliximab is still reserved for more troublesome cases, but is
highly effective.
13.3.3. Sweet's syndrome
Sweet's syndrome is characterised by tender, red inflamma-
tory nodules or papules, usually affecting the upper limbs,
face or neck. It has only been recognised as an extraintestinal
manifestation of IBD relatively recently.300,301 It is part of the
group of acute neutrophilic dermatoses that includes
pyoderma gangrenosum, but can be distinguished by its
appearance, distribution and histological features. There is a
strong predilection for women (87%), patients with colonic
disease (100%) and those with other extraintestinal features
(77%). The rash is associated with active disease in 67–80%,
but may precede the onset of intestinal symptoms in 21% and
has been reported 3 months after proctocolectomy for
ulcerative colitis.
13.4. Ocular manifestations
Uveitis and episcleritis are probably the most common
extraintestinal manifestations of IBD.273,302ECCO Statement 13D
A confident diagnosis of simple episcleritis may not
require specific treatment, but if necessary will usually
respond to topical steroids [EL4, RG D]. When diagnosis is
uncertain referral to an ophthalmologist for expert
opinion and slit-lamp examination is recommended [EL4,
RG D]. Uveitis is treated with steroids, and it may be
necessary to use both topical and systemic routes [EL3b,
RG C]. Immunomodulatory therapy has been thought
helpful in resistant cases [EL4, RG D]13.4.1. Episcleritis
Episcleritis may be painless, presenting simply with
hyperaemic sclera and conjunctiva, but itching and
burning sensations may also occur.303 Diagnosis of simple
episcleritis depends on the exclusion of the more sinister
features of uveitis. When this is not possible referral to an
ophthalmologist for an expert opinion and slit-lamp
examination is essential. Episcleritis usually does not
require specific treatment other than for underlying
disease activity. It will respond to topical steroids if
symptoms are troublesome — but take care that infection
(including herpetic), ulceration, and uveitis are not
overlooked.
13.4.2. Uveitis
Uveitis is less common, but has potentially severe
consequences. When related to ulcerative colitis it is
frequently bilateral, insidious in onset and long-lasting.304
Patients complain of eye pain, blurred vision, photophobia
and headaches. Potential progression to loss of vision
should prompt urgent referral to an ophthalmologist. Slit-
lamp examination will confirm the diagnosis and differ-
entiates between anterior and posterior uveitis. Uveitis is
treated with steroids, and it may be necessary to use both
topical and systemic routes. Infliximab is rapidly effec-
tive,304 but treatment should be guided by specialists.
13.4.3. Cataracts
Chronic corticosteroid use for treatment of UC is associated
with numerous complications and may result in posterior
subcapsular cataracts develop in a significant proportion
(25%) of patients receiving 15 mg or more of prednisone for
1 year.305 Although steroids do not prevent relapse and have
no place in the long-termmanagement of UC, any patient on
long-term steroids should undergo routine (probably annual)
slit lamp examination.
13.5. Hepatobiliary disease
Hepatobiliary disease is relatively common in IBD and
magnetic resonance cholangiography (MRC) indicates that
it may be more prevalent than currently estimated in
ulcerative colitis.306 Primary sclerosing cholangitis (PSC)
constitutes the most important condition relatively specific
to the underlying IBD. Other conditions associated with IBD
more commonly than in the general population include
pericholangitis, steatosis, chronic hepatitis, cirrhosis, and
gallstone formation. Hepatotoxicity from some drugs used
for colitis should always be considered, although usually
presents within 3 weeks of starting medication and not at
later stages.
The finding of abnormal liver function tests, rather than
symptoms or signs of liver disease, is the most common
presentation. Diagnosis of hepatobiliary disorders then
follows the standard investigatory pathways for abnormal
liver function tests, with ultrasound scanning, serology to
identify specific auto-immune or infective causes, and
liver biopsy. Predominantly cholestasis or the biliary-type
pain will prompt ultrasonographic assessment, which may
reveal gall stones, steatosis, be consistent with cirrhosis,
or (less often) show an abnormal duct pattern suggestive of
PSC.
ECCO Statement 13E
PSC appears to respond to ursodeoxycholic acid, which
improves abnormal liver function tests [EL1b, RG B] and
may, at 20 mg/kg, improve liver histology and prognosis
[EL2a, RG C]. It is possible that ursodeoxycholic acid also
reduces the risk of colonic cancer in PSC patients [EL2a,
RG C]. ERCP may be used to treat dominant strictures by
dilatation and/or stenting [EL4, RG C]. Advanced liver
disease may necessitate transplantation [EL2a, RG B]
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For patients with cholestasis the probability of PSC is
appreciably increased if the ultrasound scan is normal, if drug
side-effects are thought unlikely, and if serological tests for
primary liver disease are negative. Magnetic resonance cholan-
giography (MRC) is now established as the first-line diagnostic
test for PSC.307 The characteristic pattern shows irregular bile
ducts, with zones of both narrowing and dilatation. If MRC is
normal and PSC still suspected (such as otherwise unexplained
cholestasis in a patient with IBD), then it is safer and probably
more effective to do a liver biopsy rather than diagnostic ERCP,
since this will detect predominant small duct disease. PSC
substantially increases the risk of both cholangiocarcinoma and
colorectal carcinoma (Section 9.1.2, 9.5).
PSC appears to respond to ursodeoxycholic acid (ursodiol),
which improves abnormal liver function tests308 and may, at
20 mg/kg, possibly improve prognosis. It is possible that it also
reduces the risk of colonic cancer in these patients118 (Section
9.5). Tacrolimus has yielded a rapid decrease in liver enzymes,
but no histological improvement.309 ERCP may be used to treat
dominant strictures by dilatation and/or stenting. Advanced
liver diseasemay necessitate transplantation, but recurrence of
PSC in the transplanted liver occurs in approximately 20% of
patients.308,310 Specialist advice is appropriatewhenmanaginga
patientwithPSCand IBD. Becauseof thehigher risk of colorectal
cancer, it is generally considered appropriate to perform annual
screening colonoscopy from the time of diagnosis.
13.6. Metabolic bone diseaseECCO Statement 13E
Diagnosis of osteoporosis in adults is best made from a T
score of less than −2.5 on radiographic bone densitometry
[EL1a, RG A], all other diagnostic methods having current
limitations [EL2b, RG B]. The presence of osteoporosis
identifies patients at above average risk for fracture and
who should receive treatment [EL2b, RG B]
ECCO Statement 13G
Weight-bearing exercise [EL2b, RG B], stopping smoking
[EL3b, RG C], avoiding alcohol excess [EL4, RG D], and
maintaining adequate dietary calcium (N1 g/day) [EL2b,
RG B] are beneficial. In post-menopausal women with
osteoporosis, regular use of bisphosphonates, calcitonin
and its derivatives, and raloxifene reduce or prevent
further bone loss [EL2b, RG C]. Data in males with
osteoporosis are less secure but bisphosphonates are
probably of value [EL3b, RG C]. Newer data also support
the use of strontium salts [EL2a, RG B]ECCO Statement 13F
Osteopenia may be a prognostic marker for future
osteoporosis, but presents little direct risk [EL2b, RG C].
However if the T score is less than −1.5, treatment with
calcium, vitamin D and a bisphosphonate should be
considered [EL4, RG C]. Pre-existing history of fracture is
of substantial adverse prognostic significance and such
patients should be treated for osteoporosis even if the T
score is normal [EL4, RG C]13.6.1. Diagnosis and fracture risk
Osteoporosis and osteopenia are common in patients with
IBD (20–50%), but the actual number of fractures in IBD is
only slightly increased to the general population.311,312 In a
study using the general practice research database, the
relative risk of hip fracture was 1.62 (95% CI 1.24–2.11) for
all IBD, 1.49 (1.04–2.15) for ulcerative colitis and 2.08
(1.36–3.18) for Crohn's disease.312 Contributing factors
include age, steroid treatment, smoking, low physical activ-
ity (including that from hospitalisation), inflammatory
cytokines, and probably also resection with pouch formation.
Diagnosis is conventionally based on bone densitometry
(DEXA scanning), osteoporosis being defined as a T score of
less than −2.5. Ultrasound has been suggested as method of
screening, but is not yet reliable. The presence of osteo-
porosis increases the risk of fracture of long bones and of the
spine, although probably a great deal less in young patients
than was once thought. It is conventional to use a radiological
diagnosis of osteoporosis as an indication for specific therapy.
Osteopenia (T score less than −1.0) is thought by some to
be an important risk factor for fracture in its own right, but
this is increasingly questioned.313 It is, however, probable
that it is a marker of increased risk of later osteoporosis even
if the risk is not absolute. Therapeutic intervention is
probably not justified on present knowledge, but continued
surveillance for bone loss is appropriate. It is important to
put risks into perspective when discussing with patients.
The risks of osteoporosis (and the potential risks from
osteopenia) should be explained. The recommended dietary
calcium intake should be1000–1500mg/day,which oftenmeans
supplementation even in patients not taking corticosteroids. It
should be noted that recommendations for the treatment of
osteoporosisapplyonlytoadultsovertheageof25years,andthat
evidence for treating oestopenia is circumstantial. Thediagnosis
of osteoporosis in children and long-term consequences of
treatmentwith bisphosphonates are unknown.
13.6.2. ManagementThe risks of osteoporosis (and the potential risks from
osteopenia) should be explained. The treatment of osteoporosis
is based on studies that are not specific to IBD.314 Weight-
bearing, isometric exercise, stopping smoking, avoiding alcohol
excess and maintaining adequate dietary calcium (N1 g/day)
are beneficial, but such advice is often overlooked. Hormone
replacement treatment is no longer generally advised in post-
menopausal women with osteoporosis, because studies have
demonstrated a slightly increased risk of breast cancer and of
ECCO Statement 13A
Alternative medicines for ulcerative colitis (UC) exclude
the possibility of using conventional therapy at the same
time [EL5, RG D]. Complementary medicines for UC allow
concomitant conventional therapy [EL5, RG D]
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calcitonin and its derivatives, and raloxifene (a selective
oestrogen receptor modulator) may reduce or prevent further
bone loss. Data in males with osteoporosis are few, but
bisphosphonates are probably of value and an important
practice point is that testosterone should be measured. Those
with low testosterone may benefit from supplementation.
Routine administration of vitamin D is not warranted. Patients
on corticosteroids for short periods do not merit routine use of
bone protection with bisphosphonates, assuming a normal
calcium intake and all other risk factors being equal.315
13.7. Other systems
Other systems are found to be abnormal in UC more often than
would be expected by chance and these associations may
therefore be considered to be extra-intestinal manifestations.
Examples include respiratory complaints (especially asthma),
cardiac and pericarditic conditions, nephrological disease (both
nephritis and amyloidosis), neurological conditions (especially
multiple sclerosis) and urinary tract stones.274,302 Their diag-
nosis and management is not considered in further detail,
because the routes to diagnosis are no different from those in
general medical practice and because their management is
fundamentally independent of that of the colitis. The issue of
interstitial nephritis associated with 5-ASA therapy316 is
considered in the section on colitis therapy (Section 5.4.1,
preceding paper same issue.)289 Anaemia and ulcerative colitis
deserves greater proactive management by gastroenterologists
than it generally receives, because it is associated with
substantial impairment of the quality of life. Reasons for not
treating anaemia effectively often dwell on intolerance to oral
iron therapy and difficulty in delivering or risks associated with
parenteral iron, but this is no longer tenable and expectations of
both patients and physicians should be raised.276
13.8. Organisation of services for EIMs associated
with ulcerative colitisECCO Statement 13 G
Organisation of services to facilitate expert management
of extra-intestinal manifestation may include combined
or parallel specialist clinics conducted with clinicians
ECCO Statement 13B
Alternative medicine for UC as defined above is strongly
discouraged [EL5, RG D]Themorecommonextra-intestinalmanifestations affecting
joints and skin may be profitably managed by a close working
relationship between the gastroenterologist and rheumatolo-
gist or dermatologist respectively. It is easier to ensure that
inter-disciplinary knowledge is used to best advantage for the
patient by the existence of periodic clinics for rheumatology,
dermatology and other specialties held in parallel, and in some
cases by joint consultations. Awareness of atypical presenta-
tions and of new exploratory therapies is therefore enhanced.
14. Complementary and alternative medicines
14.1. Introduction
The use of complementary and alternative medicine among
UC patients is common, and physicians are frequently
from the other relevant disciplines [EL4, RG D]confronted with questions about their use. Reasons for
using such therapies are worries about conventional treat-
ment, including perceived lack of effectiveness and fear
about side-effects, in addition to subjective benefit from
complementary or alternative therapies. However, evidence
for the efficacy and safety of CAMs is often lacking, because
there are very few controlled trials that assessed these
therapies in UC and even these are underpowered for what
they aim to establish. Consequently, because of the lack of
power and other methodological problems in the reported
studies, it is difficult for physicians to inform their patients
adequately. Nevertheless, complementary and alternative
treatments warrant further evaluation from public interest
alone. Although complementary medicine appears to be
generally safe and non-toxic, this cannot be assumed and
potential side-effects should be considered for each sub-
stance, particularly when microorganisms are used in
conjunction with conventional immunomodulators.
14.2. DefinitionsComplementary and alternative medicines represent a
diverse group of medical and non-medical products and
therapeutic approaches that are not presently considered part
of conventional therapy. Products that have established efficacy
in UC, such as specific probiotics (E. coli Nissle 1917, for
example), are not considered complementary or alternative
medicines and are described elsewhere (Section 6.2.4, preced-
ing paper same issue). On the other, hand remedies from
different, often non-Western, cultures are included in this group
of therapies, as well as those that are unproven. An important
distinction between alternative and complementarymedicine is
its relation to conventional therapy. Alternative medicine
explicitly excludes concomitant conventional therapy, but
complementary medicine allows the complementary approach
in conjunctionwith conventional therapy. It is helpful if patients
are aware of this distinction, not least because alternative
medicine for a serious, potentially life-threatening condition
such as acute severe colitis would be dangerous.
14.3. Use of CAMSince alternative medicine by definition does not allow
conventional therapy, even when necessary, this type of UC
therapy can lead to severe complications from the underlying
condition. In contrast, complementary medicine is usually safe
and is possible if patientswant touse it. Fromapractical point of
view, if patients discuss complementary therapy in the context
of conventional medical consultation, it is usually an indicator
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condition, the conventional medicine that is being prescribes,
and the therapeutic strategy. It should alert practitioners to
unmet need, if only for more detailed explanation.ECCO Sttatement 13C
UC patients should be asked about the use of alternative
and complementary medicines [EL5, RG D]Complementary and alternative medicines are commonly
used by UC patients.317–321 Although the use of complemen-
tary medicine is considered largely safe, there are published
case reports on systemic fungal infection in immunocompro-
mised patients.321 In addition, herbal medicine such as St
John's Wort, can interact with immunosuppressive agents
and need to be checked for potential interactions.322,323 It is
therefore appropriate to enquire about the use of alternative
and complementary medicine.ECCO Statement 13D
There is insufficient evidence for the use of Trichuris suis
ova, Saccharomyces boulardii, or Bifidobacteria in the
treatment of UC [EL5, RG D]Although some probiotics and one helminth have been
investigated in clinical studies, these publications are
considered of insufficient power to take a view on whether
to recommend their use. Their design was single centre and
sample size too small.324–329ECCO Statement 13E
There is insufficient evidence for the use of acupuncture,
Boswellia serrata gum, germinated barley, aloe vera gel
and other herbal medicines in the treatment of UC [EL5,
RG D]Other complementarymedicines have been studied in small
studies or in countries where randomised, double-blind,
placebo-controlled trials are not the practice norm for judging
the merits of therapy. Because of sample size, study design,
concomitant therapies and questionable transferability, the
following agents cannot currently be recommended for
treating UC, either active disease or as maintenance:
acupuncture,330–332 Boswellia serrata gum,333 prebiotic ger-
minated barley foodstuff,334–336 aloe vera gel337 and other
herbal medicines.338 A report on curcuminmaintenance thera-
py (2 g daily, added to aminosalicylates for 6 months) showed a
signal for benefit in a double-blind, placebo-controlled trial of
89 patients.339 This both needs confirmation and illustrates the
need to explore complementarymedicines subject to the same
rigorous proof of benefit as conventional therapy.340
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